18-0! You can't get any better than that. There's little doubt that Merck's (NYSE: MRK) boceprevir will gain Food and Drug Administration approval. Merck is even trumpeting the trade name Victrelis for its new hepatitis C drug.

Victory-elis is more like it.

There was only one voting question: Do the available data support approval of boceprevir? To which the panel of experts gave a resounding yes.

But there were actually five questions the agency posed to the committee, two of which could affect sales of the drug in a major way. The panel was asked, for instance, how to handle the treatment of specific subsets of patients, such as blacks or those who failed a previous treatment. The FDA will take the panel's input, which was somewhat negative, into account in determining the label that guides doctors' prescriptions.

If Victrelis was the only option to add to the current standard of care, the label wouldn't be that big of a deal. Victrelis or nothing? Doctors would pick Victrelis.

But Victrelis will go up against Vertex Pharmaceuticals' (Nasdaq: VRTX) telaprevir, which the FDA advisory committee is reviewing today. The data on telaprevir generally look better than Victrelis, so the exclusion of any patient populations on Victrelis' label would only make it harder to compete with telaprevir and upcoming drugs from Bristol-Myers Squibb (NYSE: BMY), Pharmasset (Nasdaq: VRUS), Gilead Sciences (Nasdaq: GILD), and others.

It doesn't look like we'll have to wait too long to see the label. Merck said its PDUFA date is in mid-May. And the chance of anything less than an approval looks fairly slim.

Interested in keeping track of Merck as it gains approval of Victrelis? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Merck.

Vertex Pharmaceuticals is a Motley Fool Rule Breakers recommendation. Gilead Sciences is a Motley Fool Stock Advisor selection. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool has a disclosure policy.